Cancer is one of the most difficult disease to treat with high mortality rates of 92.3% within five years of diagnosis. A major challenge encountered in cancer drug discovery and development is  high attrition rates of development candidates in clinical trials due to lack of efficacy. This lack of efficacy in clinical studies has been attributed to low accuracy of preclinical models to predict efficacy of compounds in the clinic. As a result, preclinical models with high predictive value for efficacy are urgently required.

TheraIndx offers a range of in vitro, ex vivo and in vivo preclinical models for cancer drug discovery and development. The Oncology team of TheraIndx with extensive experience in Cancer Drug Discovery and Development help our partners using our patented Artificial Intelligence based predictive models (OncoDynamiX) , 2D/3D Organoid models, Hollow Fiber models, Pharmacology models integrated with Biomarkers to help in better translation from preclinical stage to clinical development.

Hollow Fibre Models

Hollow Fiber Models form the link between in vitro efficacy and in vivo efficacy in Xenograft models of cancer. They can be effectively employed to rapidly screen many molecules for preliminary evaluation of Pharmacokinetics and Pharmacodynamics.

Advantages:
  • Rapid in vivo screen of anti-cancer molecules (few days)
  • PK and PD information obtained from the same animal
  • Prioritization of molecules for confirmatory studies in xenograft models

Animal Models

XENOGRAFT
  • Brain
  • Breast
  • Cervical
  • Colon
  • Hepatocellular
  • Gastric
  • Leukaemia
  • Lung
  • Melanoma
  • Ovarian
  • Pancreatic
  • Prostate
  • Renal
ORTHOTOPIC
  • Leukaemia/Lymphoma
  • Breast
  • Liver
  • Stomach
  • Kidney
  • Prostate
  • Skin
SYNGENEIC
  • Melanoma